Amarin supporters were quick to defend Vascepa Wednesday night, with some taking to Twitter to argue the negative findings from the fish oil supplement study had no bearing on Vascepa because it contains more fish oil manufactured at a higher purity.
Amarin executives will likely make the same argument if/when they're asked to comment on the Italian study during tonight's conference call.
But in the Italian study, daily use of the fish oil supplement resulted in a statistically significant reduction in triglycerides, a type of fat found in the blood believed to have a negative effect on heart health. This is exactly what Vascepa does and is the basis for the pill's approval last year.Yet now we have another study showing fish oil's role in lowering triglyceride levels, which is only a laboratory measurement, doesn't help patients avoid heart disease or reduce heart-related deaths, not even a little bit. The evidence against fish oil's benefits is growing, and Amarin will have hard time explaining why Vascepa, even at a higher dose, should perform any better. -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts